Anchorage mpox outbreak expands
Four new cases of mpox in Anchorage have been reported following a state Department of Health alert.
State health officials announced the infections, marking the highest annual case count in Alaska since 2022. Three patients received diagnoses in October, and a fourth was confirmed on Thursday, according to Dr. Joe McLaughlin, Alaska’s state epidemiologist.
None of the four infected men reported traveling outside Alaska in the month prior to developing symptoms. That lack of travel breaks a pattern from previous cases in the state, where out-of-state travel was always linked to the virus.
Officials are actively investigating the transmission chain. Dr. Randi Rollins, an epidemiologist with the U.S. Centers for Disease Control and Prevention working alongside the Alaska Department of Health, stated that the absence of travel history does not automatically prove local circulation.
They may have had exposure to somebody who traveled to Alaska, and they may be the end of that transmission line at this point. We don’t know,
Rollins said.
Two of the patients are partners, but health officials have not established other links between the infected individuals. All four patients are currently isolating and recovering.
National trends and viral clades
The current Anchorage infections mirror a broader national trajectory. Federal health data shows infections climbing across the United States following an uptick that began in March.
The virus currently spreading differs genetically from the strain behind the 2022-23 global outbreak. That earlier global wave involved clade II, whereas the current outbreak involves clade I.
Historically, the clade I strain found in Central Africa carried higher fatality rates than clade II. Public health agencies note that the current clade I variant circulating in the U.S. does not appear particularly deadly.
Symptoms and infectious windows
Mpox spreads through close contact, including sexual contact. Symptoms typically appear three to 17 days after exposure.
The initial phase brings flu-like indicators such as fever, chills, fatigue, and swollen lymph nodes. A second phase produces firm or tender skin lesions across various parts of the body, though some patients develop the rash without experiencing early symptoms.
Patients remain infectious until every lesion heals completely. Rollins noted that this recovery process usually takes two to four weeks.
Vaccine rollout in Alaska
Health officials are urging individuals at higher risk to seek vaccination. The Food and Drug Administration approved the JYNNEOS vaccine in 2019 to protect against both mpox clades and smallpox.
State immunization tracking shows that 851 Alaskans have received a first vaccine dose and 604 have received a second dose since 2022, Rollins reported.
Rare borealpox diagnoses
Like other pox diseases, it is characterized by skin lesions and some flu-like symptoms.
Differences between mpox clades and vaccine availability
What is the difference between clade I and clade II mpox?
Clade I and clade II are genetic variations of the mpox virus. The 2022 global outbreak was driven by clade II, while the virus circulating now is clade I.
Where can Alaskans get the JYNNEOS vaccine?
The two-dose vaccine is available through the Anchorage Health Department and other health providers.
Related reading